spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  anti-tumor necrosis factor 

 HSMN NewsFeed - 14 Jul 2020
TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Nov 2019
Araim Pharmaceuticals Selects Ferry Breedveld as Acting CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Mar 2016
STELARA(R) Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 4 Dec 2015
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 Jul 2013
Pfizer Provides Update on Global Regulatory Approvals and Launches of XELJANZ(R) (tofacitinib citrate) for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Mar 2013
XELJANZ(R) (tofacitinib citrate) Approved in Japan for the Treatment of Adults with Rheumatoid Arthritis (RA)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Nov 2012
Abbott Announces First Long-term Patient-reported Health Outcomes Data for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2012
U.S. Food and Drug Administration Approves Pfizer’s XELJANZ(R) (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Methotrexate
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Jun 2012
Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Peripheral Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2012
Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Non-radiographic Axial Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2011
Abbott Presents HUMIRA(R) (Adalimumab) Phase 3 Study Results for Patients with Active Non-Radiographic Axial Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 2 Nov 2011
Abbott to Present Broad Spectrum of Compelling Data for HUMIRA(R) (Adalimumab) at American College of Rheumatology Annual Scientific Meeting
Biopharmaceuticals
 HSMN NewsFeed - 23 Feb 2011
Court of Appeals Overturns $1.8 Billion Patent Verdict for Centocor Ortho Biotech Inc.
Biopharmaceuticals Litigation
 HSMN NewsFeed - 27 Sep 2010
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI(R) Label in Treatment of Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Apr 2010
REMICADE(R) Study Results Show Greater Steroid-Free Remission and Mucosal Healing Compared With Conventional Immunomodulator Azathioprine in Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 6 Oct 2009
SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Jun 2009
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Apr 2009
SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Jun 2008
Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals
 HSMN NewsFeed - 12 Jun 2008
ORENCIA(R) (abatacept) Provided an Increasing Degree of Inhibition of Structural Damage Through Three Years in Adults with Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2008
Phase 3 Data Show Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Previously Treated with Anti-TNF Agents
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2008
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Mar 2008
Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Dec 2007
Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
Biopharmaceuticals Distribution
 HSMN NewsFeed - 21 Nov 2007
Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2007
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2007
New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms Of Ankylosing Spondylitis According to Phase 3 Study Findings
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2007
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
Biopharmaceuticals
 HSMN NewsFeed - 15 Oct 2007
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 10 Jul 2007
ACTEMRA(TM) (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 15 Jun 2007
REMICADE(R) Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation
Biopharmaceuticals
 HSMN NewsFeed - 15 Jun 2007
Three Studies Suggest Abbott's HUMIRA(R) (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 7 Jun 2007
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 26 Mar 2007
European Union CHMP Recommends Approval of First and Only Biologic Treatment for Pediatric Crohn's Disease: REMICADE(R)
Biopharmaceuticals Regulatory Gastroenterology
 HSMN NewsFeed - 27 Feb 2007
HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 2 Feb 2007
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Feb 2007
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 28 Nov 2006
Millennium Initiates Phase II Trial to Evaluate MLN3897 in Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2006
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Oct 2006
FDA Expands REMICADE(R) Indication for Ulcerative Colitis: Biologic Maintains Long-Term Clinical Remission and Mucosal Healing
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 27 Sep 2006
FDA Approves REMICADE(R) for Treatment of Chronic Severe Plaque Psoriasis: Marks Major Milestone for Patients With High Disease Burden
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 May 2006
New Analysis Showed Ulcerative Colitis Patients in Clinical Remission Had Higher Rates of Employment and Lower Rates of Disability
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 May 2006
New CIMZIA (TM) Data from PRECiSE Program Reinforce Robust Efficacy in Once-Monthly Treatment of Crohn's Disease and Consistent Tolerability Profile
Biopharmaceuticals Gastroenterology
Return to NewsFeed  

 Additional items found! 36

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 36 additional stories matching:
anti-tumor necrosis factor
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.